Dexcom Inc(DXCM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 23 at 4:44 PM ET (Korea 10/24 05:44)
Full metrics table
| Index | NDX, S&P 500 | P/E | 30.76 | EPS (ttm) | 2.53 | Insider Own | 1.65% | Shs Outstand | 377.4M | Perf Week | -9.41% |
| Market Cap | 29.41B | Forward P/E | 24.91 | EPS next Y | 17.08% | Insider Trans | -2.41% | Shs Float | 371.1M | Perf Month | -10.9% |
| Enterprise Value | 28.86B | PEG | 1.17 | EPS next Q | 0.67 | Inst Own | 104.93% | Short Float | 3.78% | Perf Quarter | 6.23% |
| Income | 1.00B | P/S | 5.92 | EPS this Y | 27.85% | Inst Trans | 0.79% | Short Ratio | 3.13 | Perf Half Y | 26.59% |
| Sales | 4.97B | P/B | 11.22 | EPS next 5Y | 21.35% | ROA | 14.51% | Short Interest | 14.02M | Perf YTD | 17.43% |
| Book/sh | 6.95 | P/C | 15.11 | EPS past 3/5Y | 37.83% 10.55% | ROE | 38.49% | 52W High | -15.82% ($92.59) | Perf Year | 9.68% |
| Cash/sh | 5.16 | P/FCF | 20.93 | Sales past 3/5Y | 17.01% 19.33% | ROIC | 25% | 52W Low | 44.04% ($54.11) | Perf 3Y | -9.39% |
| Dividend Est. | - | EV/EBITDA | 20.57 | EPS Y/Y TTM | 77.43% | Gross Margin | 63.57% | Volatility(W/M) | 3.61% 2.84% | Perf 5Y | -44.97% |
| Dividend TTM | - | EV/Sales | 5.81 | Sales Y/Y TTM | 15.54% | Oper. Margin | 22.92% | ATR (14) | 2.61 | Perf 10Y | 286.42% |
| Dividend Ex-Date | - | Quick Ratio | 1.43 | EPS Q/Q | 43.63% | Profit Margin | 20.12% | RSI (14) | 32.06 | Recom | 1.44 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.73 | Sales Q/Q | 13.08% | SMA20 | -7.8% ($84.53) | Beta | 1.46 | Target Price | $97.36 |
| Payout | - | Debt/Eq | 0.53 | Earnings | 2026/10/29 | SMA50 | -10.23% ($86.82) | Rel Volume | 1.17 | Prev Close | $78.32 |
| Employees | 11100 | LT Debt/Eq | 0.53 | EPS/Sales Surpr. | 14.59% 1.4% | SMA200 | 4.89% ($74.31) | Avg Volume(3M) | 4.48M | Price | $77.94 |
| IPO | 2005/4/14 | Option/Short | Yes/Yes | Trades | 42744 | Volume | 5,218,324 | Change | -0.49% |
A global medical device company specializing in Continuous Glucose Monitoring (CGM) systems. Founded in 1999 and headquartered in San Diego, California, USA, it is a leading large-cap medical device company that operates both prescription-based medical devices and consumer models.
Over the past 1 year, roughly in the middle
16% below its 1-year high.
Traded about as much as usual. That is 117% of its average volume.
Next earnings report: October 29
3 days to go.
DXCM makes money exceptionally well
Of every $100 in sales, $22.92 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +27.9% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $2,491. Peers typically go for $1,844. Compared with its own 5-year average, it is 64% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -45.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 104.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #7 of 143 in the industry
Based on market cap of $29B.
FAQ
What kind of company is DXCM?
DXCM belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of DXCM?
The market cap of DXCM is approximately $29.4B, ranking 463 within its sector.
What is the P/E ratio of DXCM?
DXCM has a P/E ratio of approximately 30.8x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for DXCM?
DXCM has recorded a 52-week high of $92.59 and a low of $54.11.
